CoChat
Cited by 309

The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.

Safety and Efficacy of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease: A Nationwide, Multicenter Cohort Study

Open access
Tison, Alice, Quéré, Gilles, Misery, Laurent, Funck‐Brentano, Elisa, Danlos, François‐Xavier, Routier, Emilie, Robert, Caroline, Loriot, Yohann, Lambotte, Olivier, Bonniaud, Bertille, Scalbert, Camille, Maanaoui, Sarah, Lesimple, Thierry, Martinez, Stéphanie, Marcq, Marie, Chouaid, Christos, Dubos, Catherine, Brunet‐Possenti, Florence, Stavris, Chloé, Chiche, Laurent, Beneton, Nathalie, Mansard, Sandrine, Guisier, Florian, Doubre, Hélène, Skowron, François, Aubin, François, Zehou, Ouidad, Roge, Christophe, Lambert, Mickaël, Pham‐Ledard, Anne, Beylot‐Barry, Marie, Veillon, Rémi, Kramkimel, Nora, Giacchero, Damien, De Quatrebarbes, Julie, Michel, Catherine, Auliac, Jean‐Bernard, Gonzales, Gilles, Decroisette, Chantal, Le Garff, Gwenaelle, Carpiuc, Ioana, Vallerand, Hervé, Nowak, Emmanuel, Cornec, Divi, Kostine, Marie, Groupe de Cancérologie Cutanée, Groupe Français de Pneumo‐Cancérologie, and Club Rhumatismes et Inflammations · 2019 · Arthritis & Rheumatology

Abstract

Objective: Immune checkpoint inhibitors (ICI s) for cancer therapy frequently induce immune‐related adverse effects (IRAE s). Therefore, most patients with preexisting autoimmune diseases have been excluded from clinical trials of ICI s. This study was undertaken to evaluate the safety and efficacy of ICI s in patients with preexisting autoimmune disease and cancer. Methods: A retrospective cohort study was conducted from January 2017 to January 2018 via 3 French national networks of experts in oncology and autoimmunity. Adults with preexisting autoimmune disease who were receiving ICI s were assessed for the occurrence of flare of preexisting autoimmune disease, other IRAE s, and cancer response. Results: The study included 112 patients who were followed up for a median of 8 months. The most frequent preexisting autoimmune diseases were psoriasis (n = 31), rheumatoid arthritis (n = 20), and inflammatory bowel disease (n = 14). Twenty‐four patients (22%) were receiving immunosuppressive therapy at ICI initiation. Autoimmune disease flare and/or other IRAE(s) occurred in 79 patients (71%), including flare of preexisting autoimmune disease in 53 patients (47%) and/or other IRAE(s) in 47 patients (42%), with a need for immunosuppressive therapy in 48 patients (43%) and permanent discontinuation of ICI in 24 patients (21%). The median progression‐free survival was shorter in patients receiving immunosuppressive therapy at ICI initiation (3.8 months versus 12 months; P = 0.006), confirmed by multivariable analysis. The median progression‐free survival was shorter in patients who experienced a flare of preexisting autoimmune disease or other IRAE, with a trend toward better survival in the subgroup without immunosuppressant use or ICI discontinuation. Conclusion: Our findings indicate that flares or IRAE s occur frequently but are mostly manageable without ICI discontinuation in patients with a preexisting autoimmune disease. Immunosuppressive therapy at baseline is associated with poorer outcomes.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/art.41068

Cites

53 of 53 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 53 references

Cited by

Metadata

Authors
Tison, A., Quéré, G., Misery, L., Funck‐Brentano, E., Danlos, F., Routier, E., Robert, C., Loriot, Y., Lambotte, O., Bonniaud, B., Scalbert, C., Maanaoui, S., Lesimple, T., Martinez, S., Marcq, M., Chouaid, C., Dubos, C., Brunet‐Possenti, F., Stavris, C., Chiche, L., Beneton, N., Mansard, S., Guisier, F., Doubre, H., Skowron, F., Aubin, F., Zehou, O., Roge, C., Lambert, M., Pham‐Ledard, A., Beylot‐Barry, M., Veillon, R., Kramkimel, N., Giacchero, D., De Quatrebarbes, J., Michel, C., Auliac, J., Gonzales, G., Decroisette, C., Le Garff, G., Carpiuc, I., Vallerand, H., Nowak, E., Cornec, D., Kostine, M., & Groupe de Cancérologie Cutanée, G. F. D. P.
Venue
Arthritis & Rheumatology
Publisher
Wiley
Published
2019-10-21
Volume
71
Issue
12
Pages
2100-2111
ISSN
  • 2326-5191 (ISSN-L)
  • 2326-5205
OpenAlex
W2980012328
Cited by
309
References
53
FWCI
14.24
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.